James A. Cardelli PhD

Dr. Cardelli received a B.S. in Biochemistry and Molecular Biology in 1973 from the University of Illinois in Champaign-Urbana and a Ph.D. in Molecular Biology and Molecular Oncology from the University of Wisconsin in Madison, Wisconsin in 1977. Following Post-Doctoral training in Oncology and Infectious Disease, Dr. Cardelli joined the faculty in the Department of Microbiology and Immunology at LSUHSC-S. He was promoted to an Associate Professor in 1989 and a Full Professor in 1993. His laboratory focused on mechanisms of survival of intracellular pathogenic bacteria from 1985 – 2005. From 2005-2015 Dr. Cardelli’s laboratory studied the molecular mechanisms regulating tumor cell invasion. Dr. Cardelli trained over 25 graduate and post-doctoral students while on the faculty at the University of Wisconsin and LSUHSC-S and he is an author on over 130 papers. Dr. Cardelli has garnered highly relevant experience in a managerial role. In addition to his directing a laboratory that average nine personnel for over 25 years, he was Director of Basic and Translational Research from 1997 to 2012 (a division that consisted of five different research programs), he promoted a yearly cancer research symposium and e organized a biweekly seminar series. In addition, Dr. Cardelli was Co-Director (from 2005 – 2011) and became Director (2011-2014) of a drug discovery and development program named Innovative North Louisiana Experimental Therapeutics. This program successfully aided a number of investigators in drug discovery at schools throughout Louisiana generating over $7M in grant funding with a budget that totalled $1M from 2010-2014. INLET received four sponsored research agreements, and filed over 10 patent applications. INLET also developed productive interactions with other Universities including: University of Louisiana at Monroe, Louisiana Tech, Pennington Biomedical Research Center, LSUHSC-S-New Orleans, LSUHSC-S New Orleans, and LSU-S. Dr. Cardelli was named an Adjunct Professor at Louisiana Tech and ULM. Dr. Cardelli retired at the end of 2015 to start the asset and IP holding company Segue Therapeutics followed by Segue Science Management (Technology Transfer and commercialization), Segue Science Labs (Drug Discovery and Contract Research), and SegueTx-Pancreatic Cancer (Development of Repurposed drugs for Fibrosis.